DOC2B enhancement of beta cell function and survival

dc.contributor.advisorThurmond, Debbie C.
dc.contributor.advisorElmendorf, Jeffrey S.
dc.contributor.authorAslamy, Arianne
dc.contributor.otherEvans-Molina, Carmella
dc.contributor.otherBaucum, Anthony J.
dc.date.accessioned2018-05-29T17:34:59Z
dc.date.available2018-05-29T17:34:59Z
dc.date.issued2018-03-08
dc.degree.date2018en_US
dc.degree.disciplineDepartment of Cellular & Integrative Physiology
dc.degree.grantorIndiana Universityen_US
dc.degree.levelPh.D.en_US
dc.descriptionIndiana University-Purdue University Indianapolis (IUPUI)en_US
dc.description.abstractDiabetes mellitus is a complex metabolic disease that currently affects an estimated 422 million people worldwide, with incidence rates rising annually. Type 1 diabetes (T1D) accounts for 5-10% of these cases. Its complications remain a major cause of global deaths. T1D is characterized by autoimmune destruction of β-cell mass. Efforts to preserve and protect β-cell mass in the preclinical stages of T1D are limited by few blood-borne biomarkers of β-cell destruction. In healthy β-cells, insulin secretion requires soluble n-ethylmaleimide-sensitive factor-attachment protein receptor (SNARE) complexes and associated accessory regulatory proteins to promote the docking and fusion of insulin vesicles at the plasma membrane. Two target membrane (t)-SNARE proteins, Syntaxin 1/4 and SNAP25/23, and one vesicle-associated (v)-SNARE protein, VAMP2, constitute the SNARE core complex. SNARE complex assembly is also facilitated by the regulatory protein, Double C2-domain protein β (DOC2B). I hypothesized that DOC2B deficiency may underlie β-cell susceptibility to T1D damage; conversely , overexpression of DOC2B may protect β-cell mass. Indeed, with regard to DOC2B abundance, my studies show reduced levels of DOC2B in platelets and islets of prediabetic rodents and new-onset T1D humans. Remarkably, clinical islet transplantation in T1D humans restores platelet DOC2B levels, indicating a correlation With regard to protection/functional effects, DOC2B deficiency enhances susceptibility to T1D in mice, while overexpression of DOC2B selectively in β-cells protects mice from chemically induced T1D; this correlates with preservation of functional β-cell mass. Mechanistically, overexpression of DOC2B and the DOC2B peptide, C2AB, protects clonal β-cell against cytokine or thapsigargin-induced apoptosis and reduces ER stress; this is dependent on C2AB’s calcium binding capacity. C2AB is sufficient to enhance glucose stimulated insulin secretion (GSIS) and SNARE activation in clonal β-cells to the same extent as full-length DOC2B. In summary, these studies identify DOC2B as a potential biomarker and novel therapeutic target for prevention/management of T1D.en_US
dc.identifier.doi10.7912/C25W7M
dc.identifier.urihttps://hdl.handle.net/1805/16275
dc.identifier.urihttps://doi.org/10.7912/C25W7M
dc.identifier.urihttp://dx.doi.org/10.7912/C2/2025
dc.language.isoen_USen_US
dc.subjectDiabetesen_US
dc.subjectIsleten_US
dc.subjectSNAREen_US
dc.subjectBeta cellen_US
dc.subjectInsulin secretionen_US
dc.titleDOC2B enhancement of beta cell function and survivalen_US
dc.typeDissertation
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Aslamy_iupui_0104D_10285.pdf
Size:
3.26 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: